More From This Series:
Part 1: RX Review: RSV Prevention Strategies and the Changing Epidemiologic Landscape
Part 2: RX Review: Clesrovimab, RSV Education, and Immunization Uptake
RX Review: The Evolving Landscape of RSV Prevention in Pediatrics and Beyond - Episode null
RX Review: Evolving RSV Strategies Call for Multispecialty Collaboration
Published on:
In this video, the last in a 3-part series, panelists discuss future directions in the field and the importance of multispecialty collaboration.
In this special report from HCP Live and Contemporary Pediatrics RX Review, Albert Rizzo, MD, moderates a discussion with Tina Tan, MD, and Joanne Nazif, MD, for an expert discussion on recent developments and persistent gaps in managing respiratory syncytial virus (RSV).
In this clip, Tan reflects on the evolution of RSV prevention strategies since palivizumab’s approval in the 1990s.1 She notes the adoption of nirsevimab in neonatal care led to supply challenges for term infants and emphasizes the need for more data on the durability of immunity provided by the newly approved monoclonal antibody, which targets a narrower RSV epitope.
Tan and Rizzo also advocate for stronger collaboration between pediatricians, pulmonologists, and infectious disease specialists to ensure comprehensive vaccination strategies across age groups. She highlights the importance of protecting not only infants and pregnant women but also older adults who frequently live in multigenerational households and are vulnerable to severe RSV outcomes.
The panel encourages the development of multidisciplinary teams, similar to those in oncology and pulmonary care, to facilitate infectious disease management and preventive care planning. Tan also stresses that RSV is not limited to pediatrics—hospitalization and mortality burdens are highest among older adults—underscoring the urgent need for adult providers to adopt and promote RSV vaccination.
Editor's note: The FDA approved Merck's clesrovimab under the name Enflonsia last month as the latest immunization strategy for infants entering their first RSV season.3
Our Panelists:
Albert Rizzo, MD, is chief medical officer of the American Lung Association. Board certified in internal medicine, pulmonary, critical care and sleep medicine, Rizzo serves as the moderator for this panel discussion.
Tina Tan, MD, is a professor of pediatrics at the Feinberg School of Medicine at Northwestern University and an infectious disease physician. She is also medical director of the International Patient and Destination Services Program, president of the Lurie medical dental staff at Ann & Robert H. Lurie Children’s Hospital of Chicago, and president of the Infectious Disease Society of America.
Joanne Nazif, MD, is an attending physician in the division of Hospital Medicine at Children's Hospital at Montefiore. She also serves as an associate professor of pediatrics at Albert Einstein College of Medicine.
Rizzo, Tan, and Nazif report no relevant disclosures.
REFERENCES
Resch B. Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection. Hum Vaccin Immunother. 2017;13(9):2138-2149. doi:10.1080/21645515.2017.1337614
FDA Approves New Drug to Prevent RSV in Babies and Toddlers. News release. FDA. July 17, 2023. Accessed July 16, 2025. https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-prevent-rsv-babies-and-toddlers
U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season. News release. Merck. June 9, 2025. https://www.merck.com/news/u-s-fda-approves-mercks-enflonsia-clesrovimab-cfor-for-prevention-of-respiratory-syncytial-virus-rsv-lower-respiratory-tract-disease-in-infants-born-during-or-entering-their-fir/
